FRACT — The Decentralised Psychedelics Research Exchange
We connect brands, universities, and investors to fund and execute compliant psychedelic and plant-medicine research using transparent governance, advisory review, and milestone-based funding.
Apply a Project
The Problem
Psychedelic and plant-medicine research is experiencing unprecedented global growth, yet the infrastructure supporting this expansion remains fundamentally fragmented. Universities possess cutting-edge research capabilities but lack commercial partnerships to translate findings into real-world applications. Brands with promising compounds struggle to navigate the complex regulatory landscape required for legally compliant clinical trials.
Investors seeking opportunities in this emerging sector demand transparency, regulated governance structures, and clear accountability mechanisms that traditional research systems simply cannot provide. The existing model is characterised by slow approval processes, institutional silos that prevent collaboration, and frameworks incompatible with the unique requirements of modern psychedelic science.
This systemic dysfunction creates bottlenecks that delay breakthrough therapies, waste resources, and limit the potential of psychedelic medicine to address mental health crises worldwide.
The FRACT Solution
FRACT provides the comprehensive infrastructure layer necessary for compliant psychedelic research and development, bridging gaps across jurisdictions and stakeholder groups.
Capital & Custody (USA)
Regulated Delaware fundraising structures combined with licensed custodial escrow services ensure investor protection and regulatory compliance.
R&D Control (Australia)
Comprehensive ethics governance frameworks and rigorous research oversight maintained through Australian regulatory standards.
Field Operations (Thailand)
Efficient patient recruitment protocols and professionally managed clinical site coordination within compliant Thai facilities.
IP Licensing (Canada)
Post-trial intellectual property administration and commercial licensing managed through transparent Canadian frameworks.
Every project undergoes rigorous advisory board vetting and maintains milestone-tracked progress using tamper-evident digital records. This multi-jurisdictional approach leverages each country's regulatory strengths whilst maintaining unified governance standards across the entire research lifecycle.
What FRACT Does
For Brands
Transform products or molecular compounds into regulator-ready clinical evidence through professional research governance, transparent reporting mechanisms, and streamlined compliance pathways. We handle the complexity of multi-jurisdictional trials whilst you maintain focus on product development and commercialisation strategy.
For Researchers
Access non-dilutive funding opportunities without sacrificing equity or institutional autonomy. Benefit from clearly defined data rights, comprehensive ethics support, and transparent execution frameworks that accelerate research timelines whilst maintaining academic rigour and publication freedom.
For Investors
Participate in psychedelic research on a per-project basis using verified milestone tracking, licensed escrow protection, and auditable documentation systems. Gain exposure to emerging therapeutic compounds with clear risk assessment and transparent capital deployment schedules.
For Regulators
Receive consistent, comprehensive documentation packages from initial proposal through final analysis. Our standardised reporting frameworks simplify regulatory review processes and ensure compliance across international jurisdictions.
How It Works
FRACT's streamlined eight-step process transforms research concepts into commercially viable clinical evidence through transparent, milestone-based execution.
Apply
Submit your project proposal on fract.co with clearly defined endpoints, study design specifications, and preliminary budget estimates.
Advisory Review
Independent scientific, clinical, and ethics experts evaluate project merit, feasibility, and compliance requirements through structured assessment protocols.
Project Packaging
FRACT produces comprehensive investor dossiers and governance frameworks tailored to your research objectives and regulatory environment.
Listing & Matching
Approved projects are published to our network of qualified investors through secure, compliant channels with full disclosure documentation.
Funding & Escrow
Investors commit capital via Delaware Series vehicles; funds are held in licensed custodial escrow with transparent release conditions.
Execution
Partner universities and contract research organisations conduct studies under approved ethics protocols with ongoing quality oversight.
Milestones
All critical events—ethics approvals, recruitment targets, data releases, statistical analyses—receive tamper-evident digital timestamps.
Commercialisation
Resulting intellectual property is licensed to project sponsors with ongoing performance reporting and transparent royalty administration.
Advisory Board
FRACT's multidisciplinary advisory board comprises internationally recognised experts across scientific, clinical, legal, and bioethics domains. This independent panel serves as the critical quality assurance mechanism ensuring research integrity, patient safety, and investor confidence throughout the project lifecycle.
Advisory Board Responsibilities
  • Comprehensive project screening against scientific merit criteria
  • Quantitative feasibility scoring using validated assessment frameworks
  • Ethics and regulatory compliance review across multiple jurisdictions
  • Rigorous conflict-of-interest identification and mitigation protocols
  • Detailed written recommendations for all project stakeholders
The advisory board functions as an essential quality filter, providing independent validation that protects researchers, investors, and participants whilst maintaining the highest standards of scientific rigour and ethical conduct.
Milestones & Transparency
Every FRACT-managed project incorporates structured, auditable milestones that provide real-time visibility into research progress and capital deployment. Our transparent tracking system eliminates information asymmetry and builds stakeholder confidence through verifiable documentation.
Ethics Approvals
Institutional review board clearances and regulatory permissions
Tranche Releases
Scheduled capital deployment tied to verified completion events
Recruitment Updates
Real-time participant enrollment tracking against target timelines
Protocol Changes
Transparent documentation of any study amendments or deviations
1
Data Lock
Database freeze confirmation prior to statistical analysis
2
Analysis Complete
Final statistical results and clinical interpretation delivered
3
IP Assignment
Intellectual property rights formally transferred per agreement
4
Licensing Progress
Commercial licensing negotiations and revenue tracking
All stakeholders receive access to visual dashboards displaying milestone completion status, supporting documentation, and immutable cryptographically signed records for each critical event. This comprehensive transparency framework ensures accountability whilst protecting sensitive commercial and clinical information.
Case Studies
FRACT has successfully supported multiple cross-border psychedelic research programmes, coordinating collaboration between Australian universities, Thai clinical facilities, and international commercial sponsors. These case studies demonstrate our comprehensive capability to manage complex, multi-jurisdictional projects from initial concept through commercial licensing.
Sponsor Concept Development
Initial therapeutic hypothesis refined through advisory board consultation, resulting in scientifically rigorous protocol design and comprehensive feasibility assessment.
Ethics Approval Navigation
Multi-jurisdictional ethics applications prepared and submitted, achieving institutional review board clearance within projected timelines across all participating sites.
Budget & Protocol Development
Detailed financial planning and protocol documentation produced, ensuring transparent cost structures and scientifically defensible methodological approaches.
Thai Clinical Operations
Efficient patient recruitment and professional data capture conducted at compliant Thai clinical sites with rigorous quality oversight and adverse event monitoring.
Transparent Reporting
Real-time milestone documentation and stakeholder communication maintained throughout study execution, providing investors with verified progress updates.
Post-Trial Licensing
Intellectual property licensing agreements administered with transparent royalty tracking and ongoing performance reporting to all contractual parties.
These anonymised examples illustrate FRACT's proven capacity to orchestrate sophisticated research programmes whilst maintaining compliance, transparency, and stakeholder confidence across the complete research-to-commercialisation pathway.
Compliance
FRACT operates through a carefully structured multi-jurisdictional framework that leverages each country's regulatory strengths whilst maintaining unified governance standards. This strategic approach ensures comprehensive compliance across the entire research lifecycle.
United States (Delaware)
Regulated fundraising vehicles structured as Delaware Series entities, combined with licensed custodial escrow services providing investor protection and capital security under US securities regulations.
Australia
Comprehensive ethics frameworks administered through Australian institutional review boards, research oversight mechanisms, and governance documentation compliant with National Health and Medical Research Council standards.
Thailand
Clinical site operations conducted under Thai Food and Drug Administration and Department of Thai Traditional and Alternative Medicine requirements, ensuring patient safety and regulatory compliance for all trial activities.
Canada
Intellectual property holding structures and licensing administration managed through Canadian frameworks with transparent reporting mechanisms and contractual governance.

Important Legal Notice: FRACT functions as a curated platform and governance framework. All investment participation is handled through separate, compliant documentation available exclusively to qualified parties under applicable securities laws and jurisdictional requirements. We do not offer securities directly through this website.
Technology
FRACT's technology infrastructure provides the digital backbone for transparent, auditable research governance. Our platform eliminates information silos and creates a unified source of truth accessible to all authorised stakeholders throughout the project lifecycle.
Core Technology Components
Secure Stakeholder Portals
Role-based access systems for brands, researchers, investors, and advisory board members with granular permission controls
Digital Signature Infrastructure
Legally binding electronic signatures integrated across all contractual and governance documentation
Tamper-Evident Records
Cryptographically secured milestone timestamps providing immutable audit trails for all critical project events
Document Management
Audit-ready storage systems with version control, access logging, and compliance-optimised retrieval capabilities
Reporting Dashboards
Real-time visualisation tools displaying project status, milestone completion, financial deployment, and risk indicators
This integrated technology stack ensures data integrity, regulatory compliance, and stakeholder confidence whilst streamlining administrative workflows and reducing operational overhead.
ESG & Impact
FRACT's operational framework aligns with internationally recognised environmental, social, and governance principles. We recognise that psychedelic research carries profound implications for global mental health outcomes and maintain unwavering commitment to ethical excellence.
Global Health Impact
Advancing evidence-based psychedelic therapies to address mental health crises affecting millions worldwide
Research Innovation
Supporting cutting-edge scientific investigation whilst maintaining rigorous academic integrity and publication freedom
Patient Safety
Prioritising participant welfare through comprehensive ethics oversight and adverse event monitoring protocols
Environmental Responsibility
Minimising ecological impact through digital documentation systems and sustainable clinical site partnerships
Transparent Communication
Maintaining open dialogue with stakeholders, regulators, and communities throughout research programmes
Our commitment extends beyond regulatory compliance to encompass broader ethical considerations including equitable access to research findings, responsible intellectual property stewardship, and meaningful engagement with traditional medicine communities where relevant.
Frequently Asked Questions
Is FRACT a fund?
No. FRACT operates as a curated platform providing research governance infrastructure and compliant project funding coordination. We facilitate connections between research opportunities and qualified investors but do not pool capital or make investment decisions on behalf of participants.
Who conducts the research?
Research activities are performed by accredited universities and contract research organisations possessing appropriate ethics approvals, regulatory permissions, and institutional capabilities. FRACT provides governance oversight but does not directly conduct clinical trials or laboratory investigations.
Does FRACT guarantee project funding?
No. FRACT packages projects for investor consideration through comprehensive due diligence and professional documentation. Funding decisions remain separate and are subject to investor discretion, regulatory requirements, and risk assessment independent of FRACT's operational role.
Who owns the intellectual property?
Intellectual property ownership and licensing arrangements depend on specific project contracts negotiated between sponsors, research institutions, and investors. FRACT administers post-trial licensing transparently per contractual agreements but does not claim ownership of research outputs.
What qualifications are required for investors?
Investment participation requires accreditation status under applicable securities regulations and completion of jurisdiction-specific qualification procedures. Requirements vary by location and are detailed in separate offering documentation provided to qualified parties.
How are advisory board members selected?
Advisory board members undergo rigorous vetting for relevant expertise, institutional credibility, absence of conflicts of interest, and commitment to research ethics. Selection criteria emphasise scientific qualifications and regulatory experience across psychedelic medicine domains.
Contact
Get in Touch
Whether you represent a brand with promising compounds, a university research team, a qualified investor, or a regulatory body seeking information, we welcome enquiries about FRACT's governance frameworks and project opportunities.
Primary Contact
Headquarters
Delaware, United States of America
Global Operations
Australia • Thailand • Canada
Our international team typically responds to enquiries within 48 business hours. For project submissions, please use the application portal at fract.co to ensure proper routing and documentation.
Legal Disclaimer
This website contains informational content regarding FRACT's research governance services and operational framework. Nothing contained herein constitutes an offer to sell, solicitation of an offer to buy, or recommendation of any security or investment product.

Important Notice: Participation in any FRACT-coordinated research project is subject to legal eligibility verification, jurisdictional compliance requirements, and execution of separate definitive documentation. Opportunities are available exclusively to qualified parties under applicable securities laws and regulatory frameworks.
FRACT does not provide legal advice, tax guidance, or financial recommendations. Prospective participants should consult qualified independent advisors regarding suitability, risk factors, and regulatory implications relevant to their specific circumstances and jurisdictions.
Forward-looking statements regarding research outcomes, commercialisation potential, or therapeutic applications involve inherent uncertainties and should not be construed as guarantees of future results. Psychedelic research remains subject to evolving regulatory landscapes and scientific validation processes.
© 2025 FRACT Inc. All Rights Reserved.
All trademarks, service marks, and trade names referenced are property of their respective owners. Unauthorised reproduction or distribution of website content is prohibited.
Privacy & Data Protection
FRACT maintains rigorous data protection standards consistent with international privacy regulations including GDPR, PIPEDA, and applicable US state privacy laws. We implement comprehensive technical and organisational measures to safeguard sensitive research data, personal information, and commercial intellectual property.
Data Protection Principles
  • Purpose limitation and minimal data collection protocols
  • Encryption for data in transit and at rest
  • Role-based access controls with audit logging
  • Regular security assessments and penetration testing
  • Incident response procedures and breach notification protocols
  • Data retention policies aligned with regulatory requirements
Research participants' personal information is handled in strict accordance with ethics protocols and applicable privacy legislation. Clinical data transfers across jurisdictions comply with international data protection frameworks.
For detailed information regarding data processing activities, please review our complete Privacy Policy available at fract.co/privacy or contact our data protection officer at privacy@fract.co.
Join the FRACT Network
FRACT is building the infrastructure for the next generation of psychedelic medicine research. We invite qualified stakeholders to explore partnership opportunities and participate in advancing evidence-based therapeutic development.
Research Institutions
Universities and contract research organisations seeking non-dilutive funding, streamlined governance, and transparent project execution frameworks.
Commercial Sponsors
Brands with promising compounds requiring regulator-ready evidence, professional research governance, and compliant clinical trial execution.
Qualified Investors
Accredited investors seeking exposure to psychedelic research opportunities with transparent milestone tracking and regulated governance structures.
Our growing network spans multiple continents and therapeutic areas, united by commitment to scientific rigour, ethical excellence, and transparent stakeholder communication. Whether you're initiating a first research programme or expanding an established pipeline, FRACT provides the infrastructure to accelerate your objectives.
The Future of Psychedelic Research
Psychedelic medicine stands at a critical inflection point. Decades of promising preclinical research and early-phase clinical trials have generated compelling evidence for therapeutic potential across depression, PTSD, addiction, and existential distress. Yet translating this scientific promise into accessible, evidence-based treatments requires robust infrastructure connecting research capability with commercial execution.
FRACT was founded to address this infrastructure gap. We envision a future where psychedelic research operates with the same transparency, efficiency, and regulatory compliance as other medical disciplines. A future where breakthrough compounds progress seamlessly from laboratory discovery through clinical validation to patient access, supported by clear governance frameworks and stakeholder confidence.
Our Vision
Creating the foundational infrastructure layer that enables psychedelic research to scale responsibly, accelerating therapeutic development whilst maintaining unwavering commitment to scientific integrity, patient safety, and transparent communication.
Our Mission
Connecting research capability with commercial capital through compliant, transparent governance frameworks that serve brands, universities, investors, and regulators across multiple jurisdictions.
This vision requires collaboration across disciplines, jurisdictions, and stakeholder groups. It demands balancing innovation with patient protection, commercial viability with academic freedom, and regulatory compliance with operational efficiency. FRACT exists to make this balance achievable.
We invite you to join us in building the infrastructure for psychedelic medicine's next chapter. Together, we can accelerate evidence-based therapeutic development whilst upholding the highest standards of research excellence and ethical conduct.